In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews, May 2013

Executive Summary

This Month's Profile Group: Women’s Health: Moving Beyond Gynecology To Sexuality, features profiles of Evestra Pharmaceuticals, S1 Biopharma, and Sprout Pharmaceuticals. Plus these Start-Ups Across Health Care: AgPlus Diagnostics, MitaMed, Respinova, and ViroCyt.

You may also be interested in...



AgPlus Diagnostics Ltd.

AgPlus Diagnostics Ltd. has developed a rapid, handheld, low-cost diagnostic device designed to deliver quantitative results within 10 minutes. Designed to work in both clinical and non-clinical settings, it uses a patented electrochemical immunoassay in a microfluidic chip to detect the test substance, combined with a read-out from charged silver nanoparticles, which increase the sensitivity of the test and allow the use of smaller samples than other diagnostic systems.

MitaMed Ltd.

MitaMed Ltd.’s EndoVE allows for minimally invasive, non-thermal tumor ablation via the end of a standard endoscope. In conjunction with the delivery of a small dose of a chemotherapeutic, the device is placed at the tumor site, then delivers a series of eight, low-energy, electrical pulses directly to the tumor cells, increasing their porosity and thus boosting the absorption rate of the chemotherapy drug.

Respinova Ltd.

Respinova Ltd. has developed a noninvasive home-use device to help patients manage COPD’s debilitating symptoms. The PulseHaler is similar to continuous positive airway pressure devices used for sleep apnea, but it is designed to treat the very small terminal airways that are blocked as a result of COPD.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel